On the Right Track to Treat Movement Disorders: Promising Therapeutic Approaches for Parkinson’s and Huntington’s Disease

Troncoso-Escudero, Paulina; Sepúlveda, Denisse; Pérez-Arancibia, Rodrigo; Parra, Alejandra V.; Arcos, Javiera; Grunenwald, Felipe; Vidal, René L.

doi:10.3389/fnagi.2020.571185

Cited by 21 publications

(24 citation statements)

References 314 publications

(352 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although impairments appear once the loss of dopaminergic neurons in SN is already advanced, symptomatic treatment for some time with levodopa preparations, DA agonists, and monoamine oxidase-B (MAO-B) inhibitors is clinically effective ( Fox et al, 2018 ). The recommendations and descriptions of the vast repertoire of drugs available for the treatment of various aspects of PD are permanently updated, and the reader is referred to the many comprehensive studies that address this issue, e.g., Troncoso-Escudero et al (2020) .…”

Section: Therapeutic Applicationsmentioning

confidence: 99%

The Biology and Pathobiology of Glutamatergic, Cholinergic, and Dopaminergic Signaling in the Aging Brain

Gąsiorowska

Wydrych

Drapich

et al. 2021

Front. Aging Neurosci.

View full text Add to dashboard Cite

The elderly population is growing worldwide, with important health and socioeconomic implications. Clinical and experimental studies on aging have uncovered numerous changes in the brain, such as decreased neurogenesis, increased synaptic defects, greater metabolic stress, and enhanced inflammation. These changes are associated with cognitive decline and neurobehavioral deficits. Although aging is not a disease, it is a significant risk factor for functional worsening, affective impairment, disease exaggeration, dementia, and general disease susceptibility. Conversely, life events related to mental stress and trauma can also lead to accelerated age-associated disorders and dementia. Here, we review human studies and studies on mice and rats, such as those modeling human neurodegenerative diseases, that have helped elucidate (1) the dynamics and mechanisms underlying the biological and pathological aging of the main projecting systems in the brain (glutamatergic, cholinergic, and dopaminergic) and (2) the effect of defective glutamatergic, cholinergic, and dopaminergic projection on disabilities associated with aging and neurodegenerative disorders, such as Alzheimer’s and Parkinson’s diseases. Detailed knowledge of the mechanisms of age-related diseases can be an important element in the development of effective ways of treatment. In this context, we briefly analyze which adverse changes associated with neurodegenerative diseases in the cholinergic, glutaminergic and dopaminergic systems could be targeted by therapeutic strategies developed as a result of our better understanding of these damaging mechanisms.

show abstract

Section: Therapeutic Applicationsmentioning

confidence: 99%

The Biology and Pathobiology of Glutamatergic, Cholinergic, and Dopaminergic Signaling in the Aging Brain

Gąsiorowska

Wydrych

Drapich

et al. 2021

Front. Aging Neurosci.

View full text Add to dashboard Cite

show abstract

“…The motor symptoms of PD are primarily attributed to low dopamine levels in the brain as a consequence of the progressive loss of dopaminergic neurons [3] . Current therapies seek to improve motor symptoms by increasing dopamine levels [4] . The dopamine precursor levodopa is the most potent therapy for PD and is the gold standard for the treatment of motor symptoms, [4] , [5] but chronic administration can itself lead to motor and autonomic symptoms, particularly dyskinesia [6] , [7] .…”

Section: Introductionmentioning

confidence: 99%

“…Current therapies seek to improve motor symptoms by increasing dopamine levels [4] . The dopamine precursor levodopa is the most potent therapy for PD and is the gold standard for the treatment of motor symptoms, [4] , [5] but chronic administration can itself lead to motor and autonomic symptoms, particularly dyskinesia [6] , [7] . Dopaminergic agonists (DA) are another class of first-line PD treatments, however, DA can be associated with non-motor side effects such as hallucinations, impulse control disorders, sudden daytime sleepiness, and acute orthostasis [8] .…”

Section: Introductionmentioning

confidence: 99%

Natural history and patterns of treatment change in Parkinson’s disease: A retrospective chart review

Navaratnam

Arcona

Frıedman

et al. 2022

Clinical Parkinsonism & Related Disorders

View full text Add to dashboard Cite

Highlights PD management is complex and evolves as the disease progresses. Therapy dose escalations, switches, discontinuations, and add-ons are common. Relapses and adverse events are the most common reasons for therapy changes. Switches and dose escalations often occur within 6 months of initiation. Treatment in older patients is more cautious than in younger patients.

show abstract

“…Parkinson's disease (PD), well-characterized by loss of dopaminergic nigrostriatal neurons; Huntington's disease (HD), which causes loss of spiny, medium-sized striatal neurons; and Alzheimer's disease (AD) induced by diffuse brain atrophy, are generally known as NDs. Some disorders were often referred to as NDs, including primary dystonia or tremor [5,6]. Patients with NDs manifest with a wide variety of symptoms that often overlap and range from memory and cognitive impairment to impairment of the person's ability to walk, communicate, and breathe; these patients often have certain clinical characteristics, such Molecules 2021, 26, 5327 2 of 20 as gradual progression over the years, even reaching decades [4].…”

Section: Introductionmentioning

confidence: 99%

Therapeutic Potential of Natural Products in Treating Neurodegenerative Disorders and Their Future Prospects and Challenges

et al. 2021

View full text Add to dashboard Cite

Natural products derived from plants, as well as their bioactive compounds, have been extensively studied in recent years for their therapeutic potential in a variety of neurodegenerative diseases (NDs), including Alzheimer’s (AD), Huntington’s (HD), and Parkinson’s (PD) disease. These diseases are characterized by progressive dysfunction and loss of neuronal structure and function. There has been little progress in designing efficient treatments, despite impressive breakthroughs in our understanding of NDs. In the prevention and therapy of NDs, the use of natural products may provide great potential opportunities; however, many clinical issues have emerged regarding their use, primarily based on the lack of scientific support or proof of their effectiveness and patient safety. Since neurodegeneration is associated with a myriad of pathological processes, targeting multi-mechanisms of action and neuroprotection approaches that include preventing cell death and restoring the function of damaged neurons should be employed. In the treatment of NDs, including AD and PD, natural products have emerged as potential neuroprotective agents. This current review will highlight the therapeutic potential of numerous natural products and their bioactive compounds thatexert neuroprotective effects on the pathologies of NDs.

show abstract

On the Right Track to Treat Movement Disorders: Promising Therapeutic Approaches for Parkinson’s and Huntington’s Disease

Cited by 21 publications

References 314 publications

The Biology and Pathobiology of Glutamatergic, Cholinergic, and Dopaminergic Signaling in the Aging Brain

The Biology and Pathobiology of Glutamatergic, Cholinergic, and Dopaminergic Signaling in the Aging Brain

Natural history and patterns of treatment change in Parkinson’s disease: A retrospective chart review

Therapeutic Potential of Natural Products in Treating Neurodegenerative Disorders and Their Future Prospects and Challenges

Contact Info

Product

Resources

About